These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 1463138)
21. Pharmacovigilance in India: how safe are the new drugs? How sure are we? Joshi SR; Sapatnekar SM J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970 [No Abstract] [Full Text] [Related]
22. [Pharmaco-morbidity linking: a potential instrument for post-marketing surveillance]. Stricker BH; Herings RM; Bakker A; Valkenburg HA; Sturmans F Ned Tijdschr Geneeskd; 1990 Sep; 134(39):1886-9. PubMed ID: 2215766 [No Abstract] [Full Text] [Related]
23. [The Spanish drug surveillance system]. Laporte JR; Capellà D Med Clin (Barc); 1994 Sep; 103(9):335-6. PubMed ID: 7967892 [No Abstract] [Full Text] [Related]
24. Strategy for surveillance of adverse drug events. Bright RA Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403 [No Abstract] [Full Text] [Related]
25. An adverse drug reaction reporting program. Wasan SM; Marshall LB Can J Hosp Pharm; 1989 Dec; 42(6):239-41. PubMed ID: 10318356 [No Abstract] [Full Text] [Related]
27. [30 years' spontaneous recording systems of German physicians--results and experiences]. Kimbel KH Verh Dtsch Ges Inn Med; 1989; 95():683-6. PubMed ID: 2603503 [No Abstract] [Full Text] [Related]
28. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems. Glasser SP; Salas M; Delzell E J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697 [TBL] [Abstract][Full Text] [Related]
29. Misclassification in epidemiologic studies of adverse drug reactions using large managerial data bases. Graham DJ; Smith CR Am J Prev Med; 1988; 4(2 Suppl):15-24. PubMed ID: 3079350 [No Abstract] [Full Text] [Related]
30. A model for the future conduct of pharmacovigilance. Waller PC; Evans SJ Pharmacoepidemiol Drug Saf; 2003; 12(1):17-29. PubMed ID: 12616844 [TBL] [Abstract][Full Text] [Related]
32. [Record linkage: a technic in drug surveillance]. Péré JC; Bégaud B; Haramburu F; Albin H Therapie; 1987; 42(1):59-62. PubMed ID: 3590067 [No Abstract] [Full Text] [Related]
33. Current French system of post-marketing drug surveillance. Albengres E; Gauthier F; Tillement JP Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):312-4. PubMed ID: 2387656 [TBL] [Abstract][Full Text] [Related]
34. FDA attempting to overcome major roadblocks in monitoring drug safety. Zielinski SL J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645 [No Abstract] [Full Text] [Related]
35. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Bégaud B; Evreux JC; Jouglard J; Lagier G Therapie; 1985; 40(2):111-8. PubMed ID: 4002188 [No Abstract] [Full Text] [Related]
36. [Physician and pharmaceutical industry. II. Postmarketing surveillance]. Offerhaus L Ned Tijdschr Geneeskd; 1992 Jan; 136(1):36-41. PubMed ID: 1728761 [No Abstract] [Full Text] [Related]
37. [Methods for studying the adverse effects of drugs. I. Comparison of imputability methods: modelling and methodology]. Péré JC; Begaud B; Haramburu F; Albin H Therapie; 1984; 39(3):279-89. PubMed ID: 6463953 [No Abstract] [Full Text] [Related]
38. Measuring adverse drug reactions in a postmarketing surveillance system. Fisher S; Bryant SG; Kluge RM Psychopharmacol Bull; 1986; 22(1):272-7. PubMed ID: 3726073 [No Abstract] [Full Text] [Related]
39. Collection and analysis of drug safety data in pregnancy. Moretti M Can J Clin Pharmacol; 2007; 14(1):e34-6. PubMed ID: 17213508 [No Abstract] [Full Text] [Related]
40. Pharmaceutical postmarket review: fact or fiction? Schanz SJ Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]